MULTIPLE MYELOMA WITH FAILED REMISSION
Clinical trials for MULTIPLE MYELOMA WITH FAILED REMISSION explained in plain language.
Never miss a new study
Get alerted when new MULTIPLE MYELOMA WITH FAILED REMISSION trials appear
Sign up with your email to follow new studies for MULTIPLE MYELOMA WITH FAILED REMISSION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Hard-to-Treat myeloma: early trial of HPN217 underway
Disease control OngoingThis early-stage study is testing a new drug called HPN217 (also known as MK-4002) in about 100 people whose multiple myeloma has returned or no longer responds to standard treatments. The main goals are to check the drug's safety, find the best dose, and see how the body process…
Matched conditions: MULTIPLE MYELOMA WITH FAILED REMISSION
Phase: PHASE1 • Sponsor: Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated May 17, 2026 05:34 UTC
-
Website aims to empower myeloma patients to take charge of their health
Knowledge-focused OngoingThis study looks at whether a health technology program called All4Cure helps people with multiple myeloma become more involved in managing their own health. About 200 participants will fill out surveys over time to measure their confidence and ability to take action, as well as …
Matched conditions: MULTIPLE MYELOMA WITH FAILED REMISSION
Sponsor: All4Cure • Aim: Knowledge-focused
Last updated May 17, 2026 05:35 UTC